---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-089845"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2025-09-22T23:59:59+00:00"
generated_at: "2026-05-17T05:59:22.602630+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Onconetix subsidiary Proteomedix licenses manufacturing IP for PancreaSure test to Immunovia

## Summary
- Proteomedix provides master cell lines and IP for three of five PancreaSure biomarkers.
- Immunovia pays $700K total: two $300K payments (Sep 2025, Mar 2026) plus $100K for materials.
- Immunovia to pay 3% royalty on net sales of PancreaSure from 2026 through 2032.
- Deal enables Immunovia to purchase reagents directly from Proteomedix's supplier.
- Onconetix remains focused on commercializing its own Proclarix prostate cancer test.

## SEC filing metadata
- accession: 0001213900-25-089845
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2025-09-22T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390025089845/0001213900-25-089845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390025089845/ea0258196-8k_onconetix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-089845
- JSON: https://secwatch.observer/filing/0001213900-25-089845.json
- Plain text: https://secwatch.observer/filing/0001213900-25-089845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.